Pfizer’s vaccine, marketed as Abrysvo, resulted in an immune response in adults aged 18 to 59 who are at a higher risk of RSV disease because of underlying medical conditions after a single dose ...

Sales of Pfizer’s RSV vaccine, Abrysvo are likely to have been higher in the third quarter than the previous two quarters, in line with seasonal vaccine trends. The acquisition of Seagen closed ...

The Food and Drug Administration expanded its approval of Pfizer’s vaccine for a deadly respiratory virus to a new age group. The vaccine, called Abrysvo, has been approved for the prevention of ...

Pfizer Inc. announced that the US Food and Drug Administration (FDA) has approved Abrysvo (Respiratory Syncytial Virus Vaccine), the company’s bivalent RSV prefusion F (RSVpreF) vaccine, for the ...

Pfizer's respiratory syncytial virus (RSV) vaccine Abrysvo has become the first to be approved by the FDA for use in pregnancy to protect newborns and infants from lower respiratory tract disease ...

Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved ABRYSVO® (Respiratory Syncytial Virus Vaccine), the company’s bivalent ...

Penbraya also combines elements from Pfizer’s meningococcal vaccines Trumenba and Nimenrix, which together made around $300 million in 2023, and started shipping in the US earlier this year.

because Abrysvo wasn’t approved in the U.S. for older adults until the end of May last year. So far, Pfizer has trailed competitor GSK, which has been able to dominate the nascent RSV vaccine ...

Pfizer (PFE) announced that the U.S. FDA has approved Abrysvo, the company’s bivalent RSV prefusion F vaccine, for the prevention of lower respiratory tract disease caused by RSV in individuals ...

Pfizer stock (NYSE: PFE) is down 7% in a month, amid rising concerns over the future of vaccines under Robert ... seeing a strong uptick in Vyndaqel and Abrysvo and a continued growth in Eliquis ...